17TH JUNE 2022

. ZAKARA BIOMEDICAL INNOVATION

WEB SERIES
SCAN TO REGISTER SCAN TO REGISTER

UROLOGY SOCIETY OF PUNE

&
ZAKARA SCIENTIFIC PTE. LTD. (SINGAPORE)
INVITE YOU TO JOIN IN THE DISCUSSION ON

SESSION 1: CLINICAL IMPACT OF URINE BIOPSY FOR BLADDER CANCER DETECTION

11TH SEPTEMBER
HIGHLY SENSITIVE PROTEIN BIOMARKERS2021
HAVE BEEN INSTRUMENTAL IN DETECTING AT HIGH EFFICACY THE PRESENCE OF BLADDER
CANCER. THE NON-INVASIVE DIAGNOSIS TEST THROUGH URINE BIOPSY REVOLUTIONIZES ITS COMPLEMENTARY TOOL IN SUPPORTING
CLINICIANS IN DETECTING ALL STAGES OF BLADDER CANCER FOR FOLLOW UP ACTIONS. ITS HIGH CLINICAL UTILITY IS ALSO SHARED TO
ALLOW FOR EFFORTLESS AND PROMPT RESPONSES TO BE MADE AVAILABLE TO ALL RELEVANT PATIENTS.

PROF JEAN PAUL THIERY. MD

RECIPIENT OF THE FRENCH ORDER OF THE MERIT IN 1997 AND
KNIGHT OF THE LEGION OF HONOR IN 2009.
Jean Paul Thiery has made seminal contributions in the fields of cell adhesion, cell migration, morphogenesis, and cancer,
publishing more than 500 peer-reviewed articles in different areas of the life sciences. He has worked at CNRS together with Prof Gerald
Edelman, Nobel laureate in Medicine, discovering the first cell-cell adhesion molecule: N-CAM. N-CAM, co-discovered the most prevalent
mutation (FGFR3) in superficial bladder carcinoma, showing that metastatic carcinoma exhibiting FGFR3 translocated to TACC3 respond
remarkably to pan-FGFR inhibitors. co-founding the Ig superfamily of more than 700 members in the human genome. He is actively
pursuing identification of therapeutic strategies abrogating epithelial cell plasticity driving carcinoma invasion and metastasis.

SESSION 2: CLINICAL UTILITY OF NGS LIQUID BIOPSY IN METASTATIC CASTRATION-

RESISTANT PROSTRATE CANCER &
THE IMPORTANCE OF SENSITIVITY AND SPECIFICITY IN CTDNA ASSAYS
THERE HAS BEEN SUBSTANTIAL GROWTH IN THE NUMBER OF ACTIONABLE BIOMARKERS WITH APPROVED TARGETED THERAPIES BRINGING ABOUT
SIGNIFICANT SURVIVAL BENEFITS IN SEVERAL CANCER TYPES IN RECENT YEARS. PROF ARUN WILL SHARE ON ITS CLINICAL UTILITY TOWARDS METASTATIC
CASTRATION-RESISTANT PROSTRATE CANER. THIS WILL BE FOLLOWED BY DR MERKLE WHO HIGHLIGHTS THE RELEVANCE OF HIGH SENSITIVITY AND
SPECIFICITY OF CTDNA ASSAYS IN ORDER FOR ANY TEST TO BE EFFECTIVE AND RELEVANT AS A RELIABLE DIAGNOSIS TOOL.

PROF ARUN AZAD. MD DR. DENNIS MERKLE, PHD, DR. VILAS SABALE MD,
PETER MACCALLUM CANCER CEO FOR PREDICINE INC. PROF & HOD OF UROLOGY
CENTRE, AUSTRALIA EUROPE DY PATIL HOSPITAL & SABALE
Prof Azad is a medical oncologist Dr. Merkle has over 20 years' SUPERSPECIALITY HOSPITAL.
and translational researcher in experience in cancer biology, Dr. Sabale is Consultant
prostate and urological cancers. Based at Peter molecular and companion diagnostics and Urosurgeon & Andrologist, MS-General
MacCallum Cancer Centre, he is a Professor at drug development, he has also held senior Surgery, MCh (Urology), DNB-Genito Renal
University of Melbourne and Translational Research positions in marketing and R&D at Merck Transplant and uro-oncosurgery. Has guided
Sub-Committee Chair at the ANZUP Cancer Trials KGaA, Abbott Laboratories and Philips more than 20 M.Ch Urology students at the
Group. He is also Co-Lead of the Movember/Cancer building with extensive experience in the Department of Urology, DY Patil Medical
Australia Up-Front PSMA Prostate Cancer Research development and launch of novel drug and College, and has more than 25 publications in
Alliance. diagnostic products. national and international Urology Journals.
QUESTION AND ANSWER SESSION: MODERATED BY DR VILAS SABALE. UROLOGY SOCIETY OF PUNE
PROGRAMME
6.00 pm Introduction 7.30 pm Talk by Dr Dennis Merkle Date: 17th June 2022.
6.05 pm Talk by Prof J . P. Thiery 7.45 pm Q & A (Part 2) Time: 06:00 PM to 08.00 pm
6.45 pm Q & A (Part 1) 7.55 pm Research Discussion V e n u e : U r o l o g y So c i e t y P u n e / O n l i n e
7.00 pm Talk by Prof Arun Azad 8.00 pm End of Programme Registration: https://tinyurl.com/2ftjar7v
BROUGHT TO YOU BY
Z A K A R A P T E . L T D . ( S I N G A P O R E ) | ZAKARA SCIENTIFIC PVT. LTD. (INDIA)
I N A S S O C I A T I O N W I T H
UROLOGY SOCIETY OF PUNE |BIOCHEETAH PTE LTD (SINGAPORE) |PREDICINE INC. (USA)

Z A K A R A P R I V A T E L I M I T E D
HQ: #7 TEMASEK BOULEVARD SINGAPORE 038987 | EMAIL: SALES@ZAKARA.ORG | PHONE: +6587645177
E: INFO@ZAKARASCIENTIFIC.COM | PHONE: +6587645177 (SG) | +91 9607 88 0077 (IN)